Kallikrein-related peptidase 13 ( KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas

Gastric cancer is a fatal human malignancy with poor prognosis. Modifications in gene expression, including those of the kallikrein-related peptidase family, have been portrayed in gastric carcinogenesis. Given KLK13 involvement in human malignancies, we aimed to uncover its prognostic strength in s...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2010-10, Vol.43 (15), p.1205-1211
Main Authors: Konstantoudakis, George, Florou, Dimitra, Mavridis, Konstantinos, Papadopoulos, Iordanis N., Scorilas, Andreas
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarker
Carcinogenesis
Cell Line, Tumor
Disease-Free Survival
Gastroenterology. Liver. Pancreas. Abdomen
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Humans
Kallikrein-related peptidases
Kallikreins - genetics
Kallikreins - metabolism
Kaplan-Meier Estimate
KLK13
Logistic Models
Medical sciences
Middle Aged
Prognosis
Reference Standards
Reverse Transcriptase Polymerase Chain Reaction
Stomach - metabolism
Stomach - pathology
Stomach cancer patients’ survival
Stomach Neoplasms - diagnosis
Stomach Neoplasms - genetics
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer is a fatal human malignancy with poor prognosis. Modifications in gene expression, including those of the kallikrein-related peptidase family, have been portrayed in gastric carcinogenesis. Given KLK13 involvement in human malignancies, we aimed to uncover its prognostic strength in stomach cancer. Quantitative analysis of KLK13 profiles was accomplished in human gastric cancer cells and in a statistically significant sample size of stomach tissue specimens with the development of the highly sensitive real-time PCR methodology. Decreased KLK13 expression was demonstrated in cancerous compared with their matching non-malignant pairs ( p = 0.002) and in poorly differentiated gastric tumors ( p = 0.029). KLK13-positive patients were shown to live considerably longer ( p = 0.014) and with low risk of disease recurrences ( p = 0.043). This is the first study disclosing the possible clinical utility of KLK13 as a new tumor biomarker capable of predicting a favorable outcome for gastric cancer patients.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2010.07.016